Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Candida spp. are the leading causes of invasive fungal infections in hospitals globally. Invasive candidiasis (IC) includes bloodstream infections (BSIs) and intra-abdominal candidiasis (IAC), which are associated with mortality rates of 20%-40% despite treatment with echinocandins (ECHs), the frontline antifungal class. IAC pathogenesis is under-studied and poorly understood compared to that of Candida BSIs. Candida glabrata is the 2nd leading cause of IC overall and the leading cause of IAC in patients undergoing abdominal surgery. C. glabrata is notable for its haploid, rather than diploid genome, and its propensity to antifungal resistance. However, most ECH treatment failures of C. glabrata IC are not linked to an ECH-resistant strain. Antifungal heteroresistance (HR, a low-frequency subpopulation of resistant cells co-existing with susceptible cells) and tolerance (some cells grow better than controls in presence of drug without minimum inhibitory concentration changes) are reported among Candida spp., but their clinical relevance is not broadly validated. The long- standing paradigm is that almost all sterile site infections, including IAC, stem from a single, clonal organism that passes through a bottleneck to establish disease. Our preliminary data challenge the “single organism” paradigm by demonstrating that blood cultures from individual patients with C. glabrata BSIs are comprised of mixed populations of genetically and phenotypically diverse strains, including strains exhibiting virulence differences and antifungal-HR or tolerance that was not recognized by the clinical lab. We do not know if this diversity was generated in the blood or during gastrointestinal (GI) tract commensalism. In this study, we will investigate C. glabrata diversity during GI tract colonization and from sites of IAC. We hypothesize that C. glabrata strains at sites of IAC originate from GI tract flora, genetic and phenotypic diversity of C. glabrata strains is present at IAC sites but less than that encountered during GI colonization, certain within-host C. glabrata genetic variants enriched in IAC cultures impact pathogenesis of IAC, and other within-host genetic variants enriched during ECH exposure impact ECH-HR or tolerance. In aim 1, we will identify phenotypic and genetic diversity of C. glabrata colonizing the GI tract and from sites of IAC in individual patients. We will recover C. glabrata strains from stool and IAC cultures in each of 6 patients, including those receiving ECH prophylaxis, and assess virulence- associated phenotypes and ECH resistance, HR and tolerance in vitro. We will perform whole genome sequencing on strains from patients in whom phenotypic differences are identified and prioritize certain genetic variants for validation studies. In aim 2, we will validate that C. glabrata genetic variants contribute to pathogenesis of IAC and/or to ECH HR or tolerance. We will create isogenic mutant C. glabrata strains for prioritized genetic variants. Strains will be tested for impact of genetic variants on phenotypes in vitro and on pathogenesis and ECH responsiveness during C. glabrata IAC of mice. This project will afford original scientific insights and carry potentially important implications for clinical and microbiology lab practices.
Grant Summary
Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $437K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $437K
2028-01-31
- 1Confirm your organization is eligible for Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis: Frequently Asked Questions
Who is eligible for the Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis?
Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis provide?
Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis provides up to $437K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis deadline?
Applications for Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis?
To apply for Candida glabrata populations during gastrointestinal tract colonization and abdominal candidiasis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.